CLX

Business Profile & Competitive Position

The Clorox Company (CLX) is a Consumer Defensive stock in the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in about 25 countries and sales in roughly 95 markets. Investors usually think of the company as a defensive staples name, but its current margin and return figures paint a mixed picture. Net margin is 8.7%, which is positive but not elite for the sector. More striking is ROE of –1893.5%, a deeply negative figure that signals equity has been substantially eroded—typically the result of high leverage, cumulative losses, buybacks, or significant balance-sheet restructuring rather than a normal return profile.

A competitive moat, if any, has to be judged mainly by brand recognition and distribution scale. Its consumer portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while professional lines include Purell, CloroxPro, and Clorox Healthcare. Yet financial-posture numbers do not show fortress economics. Customer concentration is another constraint: Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of consolidated net sales. That concentration gives incremental negotiating power to the retail channel and limits pricing flexibility.

Financial Posture

Clorox’s market capitalization is $10.1 billion, and its trailing P/E is 17.4. The stock is currently trading at $83.8, compared with a 50-day exponential moving average of $94.02, and the RSI is 34.0. The P/E near 17.4 sits in a zone that looks neither notably cheap nor notably expensive for a mature Consumer Defensive business. The beta of 0.54 is consistent with the low-volatility profile normally expected from the sector.

Profitability signals, however, are contradictory. The 8.7% net margin shows the company still converts sales into profit, but the –1893.5% ROE is a loud red flag about the capital structure. Returns measured in that way do not reflect operational earnings power; they reflect an equity base that is small or negative relative to reported results. In practical terms, Clorox is generating operating cash flow but its book equity has been substantially reduced, which means the business cannot be evaluated as though it were a typical ROE-driven compounder.

Strategic Priorities & Outlook

Clorox’s most recent 10-K describes a company in the middle of a multi-year modernization effort. The stated strategy is called IGNITE, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Operationally, the company is working to complete and optimize a new enterprise resource planning (ERP) system and a broader digital transformation aimed at long-term efficiencies across the supply chain, digital commerce, innovation, and brand building. Management says it will invest in strong brands, strategic digital capabilities, and a streamlined operating model to build a more resilient company and deliver consistent, profitable growth.

Portfolio change is also central. In April 2026 Clorox completed the acquisition of GOJO Industries, expanding its health and hygiene portfolio and strengthening its business-to-business presence. At the same time, January 31, 2026 marked the expiration of the Glad bags and wraps venture with Procter & Gamble; Clorox was required to purchase P&G’s 20% interest, while Glad retained core intellectual property licenses on a royalty-free basis.

The 10-K also notes that fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%. Part of that decline was attributed to macroeconomic headwinds, but the company also stated that ERP transition timing had pulled some sales into fiscal 2025, creating a difficult year-over-year comparison.

Macro & Geopolitical Exposure

Because Clorox sits in the Consumer Defensive / Household & Personal Products industry, its macro exposure follows the usual staples profile rather than being tied closely to the business cycle. Demand for cleaning products, trash bags, cat litter, salad dressing, and water filters is non-discretionary enough that the stock usually carries a low beta, as its 0.54 reading confirms.

That said, the industry is not without macro and geopolitical sensitivities. First, input commodities—resins, chemicals, pulp, and packaging materials—are significant cost drivers, so commodity inflation and supply-chain disruptions can compress margins. Second, because the company sells in about 95 markets, foreign exchange translation and regional tariffs can move reported results even if local operations are stable. Third, the household-products category is subject to EPA, FDA, and consumer-product regulations, as well as packaging and labeling rules that can change with political cycles. Fourth, customer concentration—already visible in the 26% Walmart exposure and roughly 50% from the top five customers—makes trade policy, retail consolidation, or pricing disputes with major distributors a structural risk for the industry.

Recent Developments

The most recent headline, dated September 28, 2026 on 247wallst.com, asks “Clorox Just Raised Its Dividend Again. Can Earnings Keep Up?” The same day the data was generated, this question captures the central investor tension: capital return is solid, but the 26% EPS decline in fiscal 2026 raises doubts about how much dividend growth the earnings base can support.

On September 24, 2026, Seeking Alpha published “Clorox's Selloff May Not Be Over Yet (Rating Downgrade),” reflecting negative institutional sentiment around the stock around the time it was already trading below its 50-day EMA. Also on September 24, 2026, PR Newswire ran a brand-driven release: “HIDDEN VALLEY® INTRODUCES SPOOKY RANCH: THE ICONIC DRESSING TAKES ON A HAUNTING HUE FOR HALLOWEEN,” illustrating the kind of seasonal marketing activity typical for a consumer packaged-goods company.

On September 23, 2026, GuruFocus reported that Clorox declared a regular quarterly dividend of $1.25 per share. Taken together, the news flow shows a stock under fundamental pressure—downgrade coverage and questions about dividend sustainability—alongside the routine brand and dividend activities investors expect from a defensive name.

Earnings Behavior & Post-Earnings Drift

Over the most recent eight reported quarters, Clorox has beaten earnings estimates 6 out of 8 times, for a 75% beat rate. The average earnings surprise across those quarters is 9.6%. In the five trading days following each of those reports, the stock has averaged a price move of +1.67%, classified as an “up” post-earnings drift. That is a memorable pattern: Clorox has tended to surprise to the upside and then drift higher over the following week.

The last four quarters show how inconsistent the next-day reaction can be, even when the company beats. On August 3, 2026, Clorox reported EPS of $1.66 against an estimate of $1.64—a 1.2% surprise—and the stock rose 6.52% the next day and 9.61% over the following five days. The prior quarter, April 30, 2026, featured a stronger beat: EPS of $1.64 versus $1.55 estimated, a 5.8% surprise. Yet the stock fell –9.67% the next day and –4.49% over five days, suggesting that the headline beat was overwhelmed by guidance, margins, or macro commentary.

On February 3, 2026, Clorox missed by –2.8% ($1.39 actual versus $1.43 estimate) but still rose 2.43% the next day and 5.63% over the following five days. The November 3, 2025 quarter was a 3.9% beat ($0.85 versus $0.818 estimate) with a modest 1.17% next-day gain but a –4.08% five-day drift. The takeaway is that the historical average favors a positive week-after drift, but the volatility around individual releases is high.

The next scheduled earnings release is November 3, 2026, after the market close, with a consensus EPS estimate of $1.11. With the stock’s RSI near 34, technically close to oversold territory, the set-up is one where the historical drift pattern may be relevant but not predictable.

For a deeper dive into how institutional analysts, quant models, and options-market positioning currently view Clorox ahead of the November earnings report, consult the full institutional verdict and aggregated sentiment dashboard rather than relying on any single metric.